Pharma Focus Asia
KP - Choose our fully recyclable blister films

Novel Therapy BXCL501 Developed for the Treatment of Dementia

BXCL501, a novel therapy developed for the acute treatment of agitation related with dementia.

BXCL501 is an investigational orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation in patients with bipolar disorders, schizophrenia and dementia. It targets agitation mechanism by giving anti-agitation results in various neuropsychiatric disorders.

Sympotoms such as psychological and agitation behaviour are often seen in 70 per cent of patients affected with Dementia. In addition, it has the negative impact on the patient and caregiver's quality of life.

Since there are no FDA approved therapies, treatment for agitation in elderly patients has become a challenge. U.S. Food and Drug Administration (FDA) has approved BXCL501 for the treatment of agitation related to Dementia.

Dementia is a neurocognitive condition causing damage to the brain cells leading to weakening of cognitive abilities and independent functioning of the brain.

In U.S, it is estimated that approximately 6 million people are affected with Alzheimer's disease accounting up to 80% of these cases.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024